Navigation Links
Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
Date:11/2/2009

on, attempts, and suicides) occurred in 2% of all patients during treatment or during follow-up after treatment cessation. PEGINTRON induced fatigue or headache in approximately two-thirds of patients, with fever or rigors in approximately half of the patients. The severity of some of these systemic symptoms (e.g., fever and headache) tends to decrease as treatment continues. There was a 23-24% incidence overall for injection site reactions or inflammation.

Individual serious adverse reactions occurred at a frequency equal to or less than 1% and included suicide attempt, suicidal ideation, severe depression; psychosis, aggressive reaction, relapse of drug addiction/overdose; nerve palsy (facial, oculomotor); cardiomyopathy, myocardial infarction, angina, pericardial effusion, retinal ischemia, retinal artery or vein thrombosis, blindness, decreased visual acuity, optic neuritis, transient ischemic attack, supraventricular arrhythmias, loss of consciousness; neutropenia, infection (sepsis, pneumonia, abscess, cellulitis); emphysema, bronchiolitis obliterans, pleural effusion, gastroenteritis, pancreatitis, gout, hyperglycemia, hyperthyroidism and hypothyroidism, autoimmune thrombocytopenia with or without purpura, rheumatoid arthritis, interstitial nephritis, lupus-like syndrome, sarcoidosis, aggravated psoriasis, urticaria, injection site necrosis, vasculitis, and phototoxicity.

Additional serious adverse events included suicide, homicidal ideation, aggressive behavior sometimes directed towards others, hallucinations, bipolar disorders, mania, encephalopathy (usually elderly treated with higher doses of PEGINTRON), hypotension, tachycardia, retinopathy including macular edema, retinal hemorrhage, cotton wool spots, papilledema, serous retinal detachment, ischemic and hemorrhagic cerebrovascular events, bone marrow toxicity (cytopenia and very rarely aplastic anemia), thyroiditis, dental and periodontal disorders, hemorrhagic/ischemic col
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Research and Markets ... Market by Equipment, by Reagent, by Application - Global ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals ... is one of the most important and widely used ... application segment of the cell culture market in 2013. ...
(Date:7/22/2014)... Mass. , July 22, 2014  Decision ... audited multiple sclerosis (MS) patients currently treated ... Tecfidera have ever experienced flushing and/or gastrointestinal ... Tecfidera-treated patients are currently experiencing these side ... the effective medical management of such events. ...
(Date:7/22/2014)... 2014 The number of people overdosing from ... day. Twenty-three percent of the workforce has misused prescription ... and Health, making opioid use a serious threat to ... at the correct dosage with a valid prescription, subtle ... National Safety Council released a guide for ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 35 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3
... Hospital today announced that revolutionary three-dimensional mammography imaging ... patient appointments at the Evergreen Breast Center, which ... Seattle area to offer the breakthrough screening and ... three-dimensional (3-D) digital imaging to create a complete ...
... Prescription drug spending growth slowed from an estimated ... according to new data released today by the Centers ... in Health Affairs. Researchers credit the slowdown in spending ... shifting medication use toward lower cost generic drugs. ...
Cached Medicine Technology:Evergreen Hospital Launches Revolutionary Breast Cancer Detection and Diagnostic Imaging Technology 2Evergreen Hospital Launches Revolutionary Breast Cancer Detection and Diagnostic Imaging Technology 3PCMA: Study Credits PBM Tools with Reducing Prescription Drug Spending Growth 2
(Date:7/22/2014)... American Society of Hematology (ASH) will honor Michael DeBaun, ... Robert P. Hebbel, MD, of the University of Minnesota ... Prize for their significant research advances in the area ... named for the late Ernest Beutler, MD, a past ... years, is a two-part lectureship that recognizes major translational ...
(Date:7/22/2014)... director of research at the University of Utah,s John ... International Society of Eye Research (ISER) as the recipient ... Kayser International Award in Retina Research., The award recognizes ... a significant contribution to the understanding of vitreoretinal diseases ... at the ISER Biennial Meeting in San Francisco, where ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Legislation ... Seniors Access to Local Pharmacies Act of 2014”) ... Part D would undermine the availability of lower ... by $21 billion over the next 10 years, ... released by the Pharmaceutical Care Management Association (PCMA). ...
(Date:7/22/2014)... WASHINGTON -- Autoimmune disorders may share certain pathogenic mechanisms ... Washington University (GW) researcher Linda Kusner, Ph.D. , ... , This paradigm shifting work shows that the very ... are also expressed in cells that produce autoimmune diseases. ... of Neurology at the GW School of Medicine and ...
(Date:7/22/2014)... The Beryl Institute announces its fifth annual Patient ... These offerings reinforce the Institute’s commitment to support the ... the need for rigorous research to understand and address ... are intended to encourage and support research into ... the patient experience before, during and after care (e.g., ...
Breaking Medicine News(10 mins):Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3
... fluid in the middle ear, a condition called otitis media ... by antihistamines and decongestants, a new review of studies has ... in alleviating symptoms or avoiding complications of OME and expose ... ,"This review finds no benefit for any of the ...
... Virginia University professor and two alumni have tracked the ... the eye and often leads to blindness and death.// ... treatment for those who suffer from it. ,Joginder ... doctoral students Jason White ('02) and Alison Director-Myska ('96) ...
... Federal government of Australia came under the glaring critics ... its allocation of funds for various health promotion programs.// ... at the current government for lapses pertaining to health ... from rural medical facilities pharmaceuticals and after hour care ...
... the gut has been found to be an effective ... researchers at Cedars-Sinai Medical Center. ,The study ... the Annals of Internal Medicine It is the ... end of the course of treatment has ended. This ...
... reports that the board of the Central Gippsland Health Service ... ,Peter Goss and Jo McCubbin had resigned from the Sale ... such an action because of threats to services. However they ... place. ,In an open letter to the hospital board, ...
... Cancer’s exploits are titillated by personality traits, contemplates a ... rodents//. The idea that personality types may increase the ... ,Researchers at the University of Chicago ... point for cancer as compared to the rats that ...
Cached Medicine News:Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 2Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 3Health News:Team Tracks Genetic Origins of Eye Cancer 2Health News:Federal government blamed for allocating meager portion to health sector:ALP 2Health News:IBS Sufferers Benefited by Non-Absorbable Antibiotics 2
... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
... Vitek is a completely automated instrument that ... 2 - 6 hour same day turnaround), ... control module. It is used for bacterial ... urine screening and has a complete data ...
IDS Rapid One, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: